<?xml version="1.0" encoding="UTF-8"?>
<p>H5N1 subtype of influenza A virus (H5N1 IAV) is a global concern with pandemic potential (classified as phase 3 alert by the World Health Organization; 
 <xref rid="ref-58" ref-type="bibr">World Health Organization, 2013</xref>). A series of outbreaks of the virus have been reported, the first of which emerged in 1997 in Hong Kong and infected 18 patients, six of whom died (
 <xref rid="ref-29" ref-type="bibr">Neumann et al., 2005</xref>; 
 <xref rid="ref-59" ref-type="bibr">World Health Organization, 2014</xref>). There were 860 confirmed human cases of avian H5N1 IAV and 454 deaths reported by WHO as of December 13, 2018 (
 <xref rid="ref-61" ref-type="bibr">World Health Organization, 2018</xref>). The annual influenza vaccine formulation is not designed for prevention of H5N1 infection (
 <xref rid="ref-57" ref-type="bibr">World Health Organization, 2012</xref>) and currently, there is no effective vaccine against the virus that is ready for widespread use.
</p>
